Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according ...
Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...
Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...
RSV cases drop in Alaska's Yukon-Kuskokwim region, Ketchikan airport parking is tight, hunters urged to try lead-free ammo, ...
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
The death comes as multiple infectious diseases are surging throughout the US, including the 10th wave of the COVID-19 ...
Respiratory illnesses have ticked up across Illinois in recent weeks. The Illinois Department of Public Health reports the ...
RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in ...
Most RSV infections are in babies less than 1 year old. But protection remains out of reach for many
Nirsevimab is made by AstraZeneca and distributed in Canada by Sanofi, under the name Beyfortus. The single injection protects infants through the fall and winter when RSV circulates regularly (as ...
Most RSV infections are in babies less than 1 year old. But protection remains out of reach for many
Nirsevimab is made by AstraZeneca and distributed in Canada by Sanofi, under the name Beyfortus. The single injection protects infants through the fall and winter when RSV circulates regularly (as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback